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Letter to the Editor
The Stomach Cancer Group
SIR.-Stomach cancer is the third most
common cancer in Britain. At present, only
1 in 6 ofthose in whom the growth is radically
resected will be alive in 5 years time and,
overall, the 5-year survival is less than 10%.
Appalled by the outlook for such patients,
this group of interested clinicians has been
meeting in an attempt to improve the treat-
ment of stomach cancer.
For the past 18 months we have entered
patients after gastrectomy to a Multicentre
Controlled Trial of cytotoxic chemotherapy.
Drug therapy is given for 2 years after
operation. The regime of 5-fluorouracil and
mitomycin-C given once every 3 weeks is
well tolerated by the patients, and the inci-
dence of side effects is low. All patients are
being closely monitored, in particular for
biochemical and haematological changes.
So far, 8 centres are involved and 137 cases
have been entered into the study. We would
welcome to this group others keen to study
this disease and its treatment.
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